Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kura Oncology and partner Kyowa Kirin announced updated Phase 1 data for the frontline combination of ziftomenib and 7+3 chemotherapy in AML. The 99-patient dataset showed high composite complete response rates of 96% in NPM1-mutant and 90% in KMT2A-rearranged patients, with MRD negativity exceeding 80% in both subtypes.
Key figures
- Drug Name
- ziftomenib (KOMZIFTI)
- Phase Of Trial
- Phase 1
- Patient count
- 99
- Crc rate npm1m
- 96%
- Crc rate kmt2ar
- 90%
- Mrd negativity npm1m
- 83%
- Mrd negativity kmt2ar
- 82%
- Median follow up npm1m
- 14.9 months
- Median follow up kmt2ar
- 9.3 months
- Median duration crc npm1m
- not reached
- Median duration crc kmt2ar
- 11.2 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.